RNA aptamer blockade of osteopontin inhibits growth and metastasis of MDA-MB231 breast cancer cells

Molecular Therapy

Volumn 17, Issue 1, 2009, Pages 153-161

  Mi, Zhiyong ^a   Guo, Hongtao ^a   Russell, M Benjamin ^a   Liu, Yingmiao ^a   Sullenger, Bruce A ^a   Kuo, Paul C ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APTAMER; GELATINASE A; HERMES ANTIGEN; JANUS KINASE 1; JANUS KINASE 2; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RNA APTAMER; UNCLASSIFIED DRUG; UROKINASE; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER INHIBITION; CELL ADHESION; CELL INVASION; CELL MIGRATION; CELL SURFACE; CONTROLLED STUDY; FEMALE; FLUORESCENCE MICROSCOPY; GEL MOBILITY SHIFT ASSAY; GENE TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; METASTASIS INHIBITION; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; APTAMERS, NUCLEOTIDE; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MICROSCOPY, CONFOCAL; NEOPLASM METASTASIS; NUCLEIC ACID CONFORMATION; OSTEOPONTIN; TRANSFECTION;

EID: 58149240891     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2008.235     Document Type: Article

References (46)

1. Denhardt, DT, Lopez, CA, Rollo, EE, Hwang, SM, An, XR and Walther, SE (1995). Osteopontin-induced modifications of cellular functions. Ann N Y Acad Sci 760: 127-142.
2. Denhardt, DT, Giachelli, CM and Rittling, SR (2001). Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41: 723-749.
3. Weber, GF, Ashkar, S and Cantor, H (1997). Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Physicians 109: 1-9.
4. Denhardt, DT and Chambers, AF (1994). Overcoming obstacles to metastasis-defenses against host defences: Osteopontin as a chield against attack by sytotoxic host cells. J Cell Biochem 56: 48-51.
5. Brown, LF, Papadopoulos-Sergiou, A, Berse, B, Manseau, EJ, Tognazzi, K, Perruzzi, CA et al. (1994). Osteopontin expression and distribution in human carcinomas. Am J Pathol 145: 610-623.
6. Agrawal, D, Chen, T, Irby, R, Quackenbush, J, Chambers, AF, Szabo, M et al. (2002). Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 94: 513-521.
7. Coppola, D, Szabo, M, Boulware, D, Muraca, P, Alsarraj, M, Chambers, AF et al. (2004). Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10: 184-190.
8. Das, R, Mahabeleshwar, GH and Kundu, GC (2003). Osteopontin stimulates cell motility and nuclear factor kappaB-mediated secretion of urokinase type plasminogen activator through phosphatidylinositol 3-kinase/Akt signaling pathways in breast cancer cells. J Biol Chem 278: 28593-28606.
9. Fedarko, NS, Jain, A, Karadag, A, Van Eman, MR and Fisher, LW (2001). Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060-4066.
10. Gotoh, M, Sakamoto, M, Kanetaka, K, Chuuma, M and Hirohashi, S (2002). Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 52: 19-24.
11. Grano, M, Mori, G, Minielli, V, Colucci, S, Vaira, S, Giannelli, G et al. (2002). HGF and M-CSF modulate adhesion of MDA-231 breast cancer cell by increasing osteopontin secretion. J Biol Regul Homeost Agents 16: 190-195.
12. Tuck, AB, Chambers, AF and Allan, AL (2007). Osteopontin overexpression in breast cancer: Knowledge gained and possible implications for clinical management. J Cell Biochem 102: 859-868.
13. Wai, PY and Kuo, PC (2004). The role of osteopontin in tumor metastasis. J Surg Res 121: 228-241.
14. Mazar, AP, Henkin, J and Goldfarb, RH (1999). The urokinase plasminogen activator system in cancer: Implications for tumor angiogenesis and metastasis. Angiogenesis 3: 15-32.
15. Que-Gewirth, NS and Sullenger, BA (2007). Gene therapy progress and prospects: RNA aptamers. Gene Ther 14: 283-291.
16. Ireson, CR and Kelland, LR (2006). Discovery and development of anticancer aptamers. Mol Cancer Ther 5: 2957-2962.
17. Gopinath, SC (2007). Methods developed for SELEX. Anal Bioanal Chem 387: 171-182.
18. Mi, Z, Oliver, T, Guo, H, Gao, C and Kuo, PC (2007). Thrombin-cleaved COOH(-) terminal osteopontin peptide binds with cyclophilin C to CD147 in murine breast cancer cells. Cancer Res 67: 4088-4097.
19. Deryugina, EI and Quigley, JP (2006). Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 25: 9-34.
20. Overall, CM and Kleifeld, O (2006). Tumour microenvironment - opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat Rev Cancer 6: 227-239.
21. Das, R, Philip, S, Mahabeleshwar, GH, Bulbule, A and Kundu, GC (2005). Osteopontin: It's role in regulation of cell motility and nuclear factor kappa B-mediated urokinase type plasminogen activator expression. IUBMB Life 57: 441-447.
22. Pillay, V, Dass, CR and Choong, PF (2007). The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol 25: 33-39.
23. Kelly, P, Moeller, BJ, Juneja, J, Booden, MA, Der, CJ, Daaka, Y et al. (2006). The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proc Natl Acad Sci USA 103: 8173-8178.
24. Wong, TY, Liew, G and Mitchell, P (2007). Clinical update: New treatments for age-related macular degeneration. Lancet 370: 204-206.
25. Daniels, DA, Chen, H, Hicke, BJ, Swiderek, KM and Gold, L (2003). A tenascin-C aptamer identified by tumor cell SELEX: Systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci USA 100: 15416-15421.
26. Zhang, L, Yoo, S, Dritschilo, A, Belyaev, I and Soldatenkov, V (2004). Targeting Ku protein for sensitizing of breast cancer cells to DNA-damage. Int J Mol Med 14: 153-159.
27. Senger, DR, Wirth, DF and Hynes, RO (1979). Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16: 885-893.
28. Fedarko, NS, Jain, A, Karadag, A and Fisher, LW (2004). Three small integrin binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases. FASEB J 18: 734-736.
29. Liapis, H, Flath, A and Kitazawa, S (1996). Integrin alpha V beta 3 expression by bone-residing breast cancer metastases. Diagn Mol Pathol 5: 127-135.
30. Wai, PY, Mi, Z, Guo, H, Sarraf-Yazdi, S, Gao, C, Wei, J et al. (2005). Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis. Carcinogenesis 26: 741-751.
31. Rangaswami, H, Bulbule, A and Kundu, GC (2006). Osteopontin: Role in cell signaling and cancer progression. Trends Cell Biol 16: 79-87.
32. Goodison, S, Urquidi, V and Tarin, D (1999). CD44 cell adhesion molecules. Mol Pathol 52: 189-196.
33. Ponta, H, Sherman, L and Herrlich, PA (2003). CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4: 33-45.
34. Gao, C, Guo, H, Downey, L, Marroquin, C, Wei, J and Kuo, PC (2003). Osteopontin-dependent CD44v6 expression and cell adhesion in HepG2 cells. Carcinogenesis 24: 1871-1878.
35. Lin, YH, Huang, CJ, Chao, JR, Chen, ST, Lee, SF, Yen, JJ et al. (2000). Coupling of osteopontin and its cell surface receptor CD44 to the cell survival response elicited by interleukin-3 or granulocyte-macrophage colony-stimulating factor. Mol Cell Biol 20: 2734-2742.
36. Zohar, R, Suzuki, N, Suzuki, K, Arora, P, Glogauer, M, McCulloch, CA et al. (2000). Intracellular osteopontin is an integral component of the CD44-ERM complex involved in cell migration. J Cell Physiol 184: 118-130.
37. Zohar, R, Cheifetz, S, McCulloch, CA and Sodek, J (1998). Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration. Eur J Oral Sci 106 (Suppl 1): 401-407.
38. Bauer, TW, Liu, W, Fan, F, Camp, ER, Yang, A, Somcio, RJ et al. (2005). Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice. Cancer Res 65: 7775-7781.
39. Mi, Z, Guo, H, Wai, PY, Gao, C and Kuo, PC (2006). Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 27: 1134-1145.
40. Philip, S and Kundu, GC (2003). Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha/IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 278: 14487-14497.
41. Tuck, AB, Hota, C and Chambers, AF (2001). Osteopontin(OPN)-induced increase in human mammary epithelial cell invasiveness is urokinase (uPA)-dependent. Breast Cancer Res Treat 70: 197-204.
42. Andreasen, PA, Kjoller, L, Christensen, L and Duffy, MJ (1997). The urokinase-type plasminogen activator system in cancer metastasis: A review. Int J Cancer 72: 1-22.
43. Das, R, Mahabeleshwar, GH and Kundu, GC (2004). Osteopontin induces AP-1-mediated secretion of urokinase-type plasminogen activator through c-Src-dependent epidermal growth factor receptor transactivation in breast cancer cells. J Biol Chem 279: 11051-11064.
44. Albini, A (1998). Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res 4: 230-241.
45. Lee, SW and Sullenger, BA (1996). Isolation of a nuclease-resistant decoy RNA that selectively blocks autoantibody binding to insulin receptors on human lymphocytes. J Exp Med 184: 315-324.
46. Jhaveri, SD and Ellington, AD (2001). In vitro selection of RNA aptamers to a protein target by filter immobilization. Curr Protoc Mol Biol Chapter 24: Unit 24.3.